A 58-year-old man with UC was admitted with acute onset pain along with swelling of the left upper extremity and left side of the neck. Doppler ultrasound of the left upper extremity and neck revealed extensive thrombosis ( Figure 1 ). Routine blood tests gave normal results except for a high erythrocyte sedimentation rate, C-reactive protein, hyperfibrinogenemia, anemia, and a significantly elevated level of lipoprotein(a) (90.5 mg/dL). A thrombophilia work-up including antiphospholipid antibody, lupus anticoagulant, homocysteine, factor VIII, D-dimer, fibrinogene, proteins C and S, antithrombin III, PT G20210A, factor V Leiden (FVL) and methylene tetrahydrofolate reductase (MTHFR) were performed. The work-up was negative except for a high level of homocystein (80 mg/dL). Genetic evaluation showed heterozygous for FVL and PT gene mutations and homozigosity for the mutation C677T of the MTHFR gene. The patient was admitted to the hospital and started on low molecular weight heparin. The patient's left arm oedema improved gradually and he had no complaints after the third month of treatment.
We identified only one other reported case of upper extremity thrombosis with UC (1). Some authors suggested that the increased incidence of thromboembolic events in UC may be caused by an increased frequency of thrombophilic mutations (2) . Other factors that may contribute to thrombosis including chronic inflammation, dehydration, decreased fibrinolytic activity and hyperhomocysteinemia have also been described in IBD (3). But recently found that homozygot MTHFR enzyme c677 on the risk of thrombosis increased risk only 10-20% in normal population (4). In our country Yasa et al. (5) showed that any corelation between IBD and most common hereditary thrombophilic factors. In conclusion thrombophilic mutations may be increase the tendency to thrombosis in IBD. But we see that the cause of thrombosis can not attribute only to this mutation. In conclusion we thought that thromboembolic events in IBD are multifactorial including thrombophilic mutations, chronic inflammation, decreased fibrinolytic activity, immobilization, use of corticosteroids, smoking and use of oral contraceptives. We need more case control series of patients complicated with venous thrombosis in order to understand the underlying mechanism of thromboembolic events in IBD.
